MDNA213-PE / Medicenna - LARVOL DELTA

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting (GlobeNewswire) - "MDNA213-PE: In vitro data demonstrate that this molecule exhibits selective and potent cytotoxic activity towards human and murine cancer cells that express IL-13Rα2. Additionally, in a murine, checkpoint inhibitor-refractory, triple-negative breast cancer model, MDNA213-PE inhibited tumor growth as a single agent and synergized with an IL-2 Superkine (MDNA19) to significantly enhance therapeutic efficacy."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer